bioAffinity Technologies (NASDAQ:BIAF) Issues Earnings Results

bioAffinity Technologies (NASDAQ:BIAF) released its quarterly earnings data on Monday. The company reported ($0.21) EPS for the quarter, Zacks reports. bioAffinity Technologies had a negative return on equity of 205.09% and a negative net margin of 91.22%. bioAffinity Technologies updated its FY 2025 guidance to EPS.

bioAffinity Technologies Stock Performance

NASDAQ:BIAF traded down $0.01 during mid-day trading on Monday, hitting $0.25. The company’s stock had a trading volume of 292,993 shares, compared to its average volume of 162,424. The business’s fifty day moving average is $0.57 and its two-hundred day moving average is $1.08. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.02 and a quick ratio of 1.01. The stock has a market cap of $3.96 million, a price-to-earnings ratio of -0.31 and a beta of 3.12. bioAffinity Technologies has a 1 year low of $0.25 and a 1 year high of $3.16.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.